Accu-Chek Aviva System Receives Arthritis Foundation's Ease-of-Use Commendation
ACCU-CHEK Aviva System is the first blood glucose monitoring system to receive ease-of-use recognition.
INDIANAPOLIS—The Arthritis Foundation has awarded its Ease-of-Use Commendation to the ACCU-CHEK Aviva system, making it the first blood glucose monitoring system to receive such recognition.
Both the ACCU-CHEK Aviva meter and test strips and the ACCU-CHEK Compact Plus drum of test strips received Ease-of-Use Commendations in 2006 because of their effective, easy-to-use designs. In December 2007, the ACCU-CHEK Multiclix lancing device, part of the ACCU-CHEK Aviva system, also passed the evaluation.
“We are proud that our products have been recognized with the Ease-of-Use Commendation by the Arthritis Foundation. The ACCU-CHEK Aviva system, with its large easy-fill test strip, easy to handle sure-grip meter, and pre-loaded lancet drum with no individual lancets to handle provides a full system designed to meet the needs of people with diabetes and arthritis,” said Roche Product Marketing Manager Cathleen Stubblefield. “We are proud of this accomplishment.”
About 60 percent of people with diabetes also have arthritis or other diseases of the joint, which can be a barrier to blood glucose testing. The Arthritis Foundation created a program to encourage manufacturers to design with ease of use in mind. The program determines the accessibility and ease of use of everyday products by allowing people with arthritis to evaluate them. Each product must pass a series of rigorous evaluations.
“Arthritis is a serious health condition that can greatly affect the quality of life for everyone, particularly people with conditions like diabetes, where self-monitoring is crucial,” said Scott Walters, group vice president for corporate relations at the Arthritis Foundation. “Through our Ease-of-Use commendation program, we hope that we can make people living with arthritis and diabetes aware of products that can help them not only maintain their independence but their health as well.”
The ACCU-CHEK Aviva system and other products that have earned the Ease-of-Use Commendation can be found on the Arthritis Foundation Web site at www.arthritis.org.
About the Arthritis Foundation
The Arthritis Foundation is the only nationwide, nonprofit health organization helping people take greater control of arthritis by leading efforts to prevent, control and cure arthritis and related diseases. The foundation reaches out to millions of men, women and children with arthritis by providing community-based public health initiatives, advocating for changes in public policy and funding research that moves us closer to a cure.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, the ACCU-CHEK brand has been committed to enable people with diabetes to live life as normal and active as possible as well as to help healthcare professionals manage their patients’ condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products and services and comprehensive solutions for convenient, efficient and effective diabetes management spanning from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems. For more information please visit www.accu-chek.com.
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection,
prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007, sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested more than 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at www.roche.com.
All trademarks used or mentioned in this release are legally protected by law.
For further information, please contact:
Public Relations Manager